Status:
UNKNOWN
Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial
Lead Sponsor:
University of British Columbia
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
45+ years
Phase:
PHASE4
Brief Summary
Large population-based studies suggest that patients with chronic obstructive pulmonary disease (COPD) are 2 to 3 times at risk for cardiovascular mortality, which accounts for a large proportion of t...
Detailed Description
What is the problem to be addressed? Patients with chronic obstructive pulmonary disease (COPD) are at increased risk of cardiovascular events. Indeed, ischemic heart disease is one of the leading cau...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- All patients must have a clinical diagnosis of chronic obstructive pulmonary disease according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines.
- Patients must have a cigarette smoking history of more than 10 pack-years
- Patients must be clinically stable and at least 4 weeks from last acute exacerbation (and return to baseline level of symptoms)
- Patients must have an FEV1 of less than 80% of predicted values with FEV1 to FVC ratio of less than 0.70 (post-bronchodilator values)
- Men or women ≥ 45 years of age
Exclusion
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
End Date :
August 1 2006
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT00120978
Start Date
December 1 2004
End Date
August 1 2006
Last Update
May 9 2006
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Calgary
Calgary, Alberta, Canada, T2V 1P9
2
Links Clinic
Edmonton, Alberta, Canada, T5G 3G6
3
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2B7
4
Grey Nuns Hospital
Edmonton, Alberta, Canada, T6L 5X8